Lung and Head and Neck cancers afflict millions of people worldwide. Their treatment requires a collaborative effort between various disciplines of medicine. At Weill Cornell Medical College/New York Presbyterian Hospital, we work closely with thoracic and ENT surgeons and medical oncologists to formulate an individualized treatment plan for each patient that is data-driven (that is, based on results of up-to-date clinical trials). We offer state of the art equipment and software to deliver the latest radiotherapy techniques, such as Image-guided Radiation therapy and Brachytherapy.
We offer participation in clinical trials designed to evaluate the effectiveness of newer and promising treatments. Eligibility for these trials will be determined during the discussion of treatment options with the radiation oncologist.
For various stages of prostate cancer, there may be multiple available options, including surgical and radiotherapeutic options. We take great pride in spending time with our patients to discuss these options, allowing them to make an informed decision as to what is the best treatment for them.
The side effects you may experience will depend on the area being treated, the type of radiation used and whether or not you also received chemotherapy. Before treatment, your doctor will describe what you can expect.
Some patients experience minor or no side effects and can continue their normal routines.
If at any time you develop side effects, tell your doctor or nurse. He or she can give you medicine to help.
Our physicians who specialize the treatment of Lung cancer and Head and Neck Cancer:
K.S. Clifford Chao, M.D: (212) 746-3608
Bhupesh Parashar, M.D: (212) 746-3612
Dattatreyudu Nori, M.D: (212) 746-3679
IRB # 1505016229 A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies NCT02383212
This study is currently recruiting participants.